Journal
Alzheimer's Research & Therapy
Publication Date
3-17-2020
Volume
12
Issue
1
First Page
26
Document Type
Open Access Publication
DOI
10.1186/s13195-020-00596-4
Rights and Permissions
Barthélemy, N.R., Bateman, R.J., Hirtz, C. et al. Cerebrospinal fluid phospho-tau T217 outperforms T181 as a biomarker for the differential diagnosis of Alzheimer’s disease and PET amyloid-positive patient identification. Alz Res Therapy 12, 26 (2020). https://doi.org/10.1186/s13195-020-00596-4 This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Recommended Citation
Barthélemy, Nicolas R; Bateman, Randall J; Hirtz, Christophe; Marin, Philippe; Becher, François; Sato, Chihiro; Gabelle, Audrey; and Lehmann, Sylvain, "Cerebrospinal fluid phospho-tau T217 outperforms T181 as a biomarker for the differential diagnosis of Alzheimer's disease and PET amyloid-positive patient identification." Alzheimer's Research & Therapy. 12, 1. 26 (2020).
https://digitalcommons.wustl.edu/open_access_pubs/9501
